Drug Name	Denosumab
Phase	Post-marketing
Approved Indications	Treatment of postmenopausal women with osteoporosis at high risk for fracture;
	Treatment to increase bone mass in men with osteoporosis at high risk of fracture; Treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for non-metastatic prostate cancer; Treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer
Mechanism of action	Suppression of bone resorption by binding to RANK ligand, preventing its binding to RANK and decreasing osteoclast formation, activity, and survival
Route of administrationChemical structure	Subcutaneous every 6 months(C6404 H9912 N1724 O2004 S50) consists of 2 heavy and 2 light chains; each light chain consists of 215 amino acids and each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. Fully human monoclonal IgG2 antibody to RANK ligand
Pivotal trials	FREEDOM, ADAMO